CytoDyn's Covid-19 drug issues escalate: Efficacy data missing from study

CytoDyn's Covid-19 drug issues escalate: Efficacy data missing from study

More reads

• CytoDyn’s Covid-19 drug troubles escalate: Efficacy data are missing from study. (STAT Plus)
• Americans are paying twice for remdesivir. (Slate)
• Gilead adds to string of cancer drug deals with Tizona stake. (BioPharma Dive)
• STAT+ Conversations: AI’s march into the clinic. (STAT Plus)